Search Results for “AstraZeneca” – Page 10 – media

AstraZeneca announces new mRNA collaboration

A five-year strategic research collaboration between AstraZeneca and its global biologics research and development arm MedImmune and Ethris, a company focussed on mRNA-based therapeutics with specific expertise in pulmonary disease.
- Source: pharmatimes
- 803
- August 22, 2017
asthma chronic collaboration Company Insight mRNA therapy
Over 5.7 billion! China’s dual antibody ADC goes global+1

On November 18th, VelaVigo Cayman Limited announced a global strategic partnership agreement with Avenzo Therapeutics, Inc. (Avenzo). According to the agreement, Orange Sail Pharmaceuticals will grant Avenzo the development, production, and commercialization of Nectin4/TROP2 bispecific antibody conjugates worldwide (excluding Greater China), while retaining relevant rights in Greater China. Both parties will jointly promote the development and clinical application of the project on a global scale. The project plans to submit an IND to the US Food and Drug Administration (FDA) and the National Medical Products Administration (NMPA) of China by 2025. According to the terms of the agreement, Orange Sail Pharmaceuticals will receive a down payment of up to $50 million and recent milestone payments. After achieving key milestones in development, regulatory approval, and sales, the company is expected to receive up to $750 million in follow-up milestone payments and tiered royalty payments based on sales in the Avenzo region. ...
- Source: drugdu
- 40
- November 21, 2024
Well-known products of foreign companies such as AZ, Eli Lilly, and Sanofi were disqualified

On November 14, the Shanxi Provincial Drug and Equipment Centralized Bidding and Procurement Center issued the “Notice on the Adjustment and Disposal of the Price of the Centralized Procurement of Amoxicillin and Other Drugs in the Guangdong Alliance” (hereinafter referred to as the “Notice”). It is worth noting that there are still 11 manufacturers and 20 specifications that refuse to reduce prices for rectification, including well-known pharmaceutical companies, including AstraZeneca, Sanofi, Eli Lilly and other foreign pharmaceutical companies, and their products include well-known brand drugs such as Plavix (clopidogrel bisulfate tablets), Iressa (gefitinib tablets), and Alimta (pemetrexed disodium for injection). The “Notice” emphasizes that the relevant drugs that refuse to accept the price rectification requirements will be disqualified from being selected and the selected price will be disqualified, and will be transferred to the alternative catalog. The platform will increase price risk warnings, and the task volume of the centralized ...
- Source: drugdu
- 32
- November 21, 2024
Semaglutide sold for $20.3 billion!

On November 6, Novo Nordisk released its third-quarter report for 2024. In the first nine months of this year, sales increased by 23% to 204.7 billion Danish kroner, of which sales of diabetes and obesity treatment drugs increased by 25% to 191.8 billion Danish kroner. The star product Semaglutide continued to advance by leaps and bounds, with sales of three brands (sugar-lowering injection Ozempic, sugar-lowering tablets Rybelsus, and weight-loss injection Wegovy) reaching 141.213 billion Danish kroner, or about 20.3 billion US dollars, in the first nine months of this year. Not long ago, Eli Lilly also announced its performance, among which the sales of two brands of GIPR/GLP-1R dual agonist Tirzepatide (Mounjaro, a hypoglycemic injection, and Zepbound, a weight loss injection) reached US$11.0284 billion in the first three quarters of this year. Specifically, Mounjaro’s sales revenue was US$8.010 billion, and Zepbound’s sales revenue was US$3.018 billion. Zepbound has been rapidly ...
- Source: drugdu
- 55
- November 9, 2024
Global New Drug Progress and New Sharing

Progress in drug research and development 1. Anjin C5aR antagonist “Avamipram” approved for market in China On November 5th, the official website of NMPA announced that the marketing application for avacopan capsules jointly developed by Anjin and CSL Vifor has been approved, presumably for the treatment of anti neutrophil cytoplasmic antibody (ANCA) – related vasculitis (AAV). Afakepan is a complement 5a receptor (C5aR) antagonist that inhibits the interaction between C5aR and the allergen C5a, blocking C5a mediated neutrophil activation and migration. The drug was approved by the US FDA in October 2021 for use in combination with standard treatment regimens including glucocorticoids to treat adult active severe ANCA associated vasculitis (MPA and GPA). In July 2024, Anjin reached an agreement with CSL Vifor to acquire commercial rights to Avamipram in Asia and Latin America, including the mainland Chinese market. 2. Pfizer PARP inhibitor “Terazopanib” approved in China On November 5th, ...
- Source: drugdu
- 70
- November 8, 2024
Lixin Pharmaceuticals Completes RMB 300 Million C1 Round of Financing

Recently, Lixin Pharmaceutical Technology (Shanghai) Co., Ltd. (hereinafter referred to as “Lixin Pharmaceutical”) announced that it has successfully completed a C1 round of financing of RMB 300 million. This round of financing was led by China Biopharmaceutical, a well-known domestic industry party, and co-invested by Pudong Venture Capital and Zhang Jianghaoheng. Old shareholders Qiming Venture Partners and Shanghai Biomedicine Fund followed suit. Zhong Lun served as the legal advisor for this round of financing. Lixin Pharmaceuticals also mentioned that it has recently launched the C2 round of financing. The funds raised will be mainly used to accelerate the clinical progress of clinical pipelines, especially LM-302 and LM-108, and support the independently developed antibody discovery platform, next-generation ADC technology platform, and bispecific antibody technology platform, and continue to produce innovative pipelines with international competitiveness. About Lixin Pharmaceuticals Lixin Pharmaceuticals is a biopharmaceutical company based in China and facing the world. It ...
- Source: drugdu
- 74
- October 28, 2024
Astellas wins a belated victory

On October 18, the FDA announced the approval of the Claudin18.2 monoclonal antibody Vyloy (zolbetuximab) for marketing, and will use it as the first-line treatment for adult patients with locally advanced unresectable or metastatic gastric cancer with Claudin18.2-positive tumors, and HER2-negative gastroesophageal junction adenocarcinoma. With the announcement of this good news, zolbetuximab officially became the first anti-Claudin18.2 drug approved by the United States. This means that Astellas has taken the lead in this hot target. In the past few years, Claudin18.2 has been a hot target in the field of oncology, attracting the interest of giants such as AstraZeneca, Merck, and Moderna. Of course, the entrants also include many domestic pharmaceutical companies. However, in the face of many entrants, Astellas’s “defending” ability has also been extremely demanding. At present, it may not be easy for it to maintain its leading position. Zolbetuximab has always attracted much attention, and the core ...
- Source: drugdu
- 66
- October 23, 2024
2.5 billion+2.3 billion! Sanofi adds more nuclear weapons

Original Xie Ling Arterial New Medicine October 18, 2024 08:27 Chongqing Yesterday (October 17th), Sanofi announced that it has reached an agreement with Orano Med, a subsidiary of the Orano Group, to further accelerate the development of next-generation radioligand therapy (RLT) by leveraging their expertise in combating rare cancers. According to the agreement, Sanofi and Oueno will jointly invest in a new entity operated under the Oueno Medical brand, focusing on the discovery, design, and clinical development of next-generation radioligand therapy (RLT) based on lead-212 (①¹² Pb) alpha emitting isotopes. Sanofi will make an equity investment of 300 million euros (approximately 2.313 billion yuan), accounting for approximately 16% of the equity of the new entity Orano Medical, with a valuation of 1.9 billion euros (approximately 14.648 billion yuan). At the beginning of last month, Sanofi announced a licensing agreement with RadioMedix and Orano Med for RLT, focusing on AlphaMedix, a ...
- Source: drugdu
- 84
- October 21, 2024
3.7 billion blockbuster antihypertensive drug, Shandong New Era approved for listing!

Yesterday (October 14), the official website of the National Medical Products Administration (NMPA) announced that the Sacubitril Valsartan Sodium Tablets submitted by Shandong New Era Pharmaceuticals were approved and passed the review. Sacubitril Valsartan Sodium Tablets is an antihypertensive drug used for adult patients with chronic heart failure with reduced ejection fraction. As the world’s first breakthrough innovative drug in the field of heart failure treatment, Sacubitril Valsartan Sodium Tablets entered the Chinese market in 2017 for the treatment of heart failure, and was later included in the 2020 National Medical Insurance Catalogue. In June 2021, it was first approved in China for the treatment of essential hypertension. In 2021, in-hospital sales exceeded 2 billion yuan in one fell swoop, a year-on-year increase of 170%. According to the Zhongkang Kaisi system, the sales of hypertension drugs in graded hospitals in 2023 will reach about 24.2 billion yuan. In the subdivided ...
- Source: drugdu
- 70
- October 17, 2024
intensified BD trading competition in the pharmaceutical market, pharmaceutical companies launch market competition war

Source: 21st Century Business Herald Has the cow arrived? The A-share market is booming, don’t miss the opportunity, open an account and layout now>> Recently, there has been a frequent wave of business development (BD) cooperation transactions between Chinese and foreign pharmaceutical companies. On October 9th, Baiaotai announced that it has reached an authorization license, production, supply, and commercialization agreement with Gedeon Richter Plc. for BAT2206 (ustekinumab) injection solution. According to the agreement, Baiaotai will license the exclusive commercial rights of the injection in the EU, UK, Switzerland, Australia, and other European markets to Gedeon Richter Plc for a fee. The amount involved in this transaction includes a down payment of $8.5 million, milestone payments up to a cumulative total of $101.5 million, and revenue sharing based on a double-digit percentage of net sales. In addition to Baiaotai, several Chinese pharmaceutical companies have also recently received positive news regarding BD ...
- Source: drugdu
- 87
- October 12, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.